Financial Performance - The company's operating revenue for the first half of 2020 was ¥337,250,361.08, a decrease of 19.65% compared to ¥419,719,990.63 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥3,789,678.16, down 92.58% from ¥51,107,158.16 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥75,196.43, a decline of 99.85% compared to ¥49,518,248.60 in the same period last year[20]. - The net cash flow from operating activities was ¥40,746,936.61, a decrease of 43.76% from ¥72,446,576.27 in the previous year[20]. - Basic earnings per share were ¥0.010, down 92.31% from ¥0.13 in the same period last year[20]. - Total assets at the end of the reporting period were ¥3,114,541,629.05, a decrease of 3.58% from ¥3,230,264,178.78 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥2,708,172,303.70, down 0.89% from ¥2,732,504,696.54 at the end of the previous year[20]. - The weighted average return on net assets was 0.14%, a decrease of 1.77% compared to 1.91% in the previous year[20]. - The company achieved a revenue of CNY 33,725.04 million, a decrease of 19.65% compared to the same period last year[44]. - The pharmaceutical manufacturing sector reported a revenue of CNY 23,806.27 million, down 28.12% year-on-year[44]. - The company reported a significant reduction in income tax expenses, which fell by 71.36% to ¥4,209,994.27 from ¥14,701,523.72 due to a decrease in taxable income[50]. - The total comprehensive income for the period decreased by 41.18% to 3,789.68 million yuan compared to the previous period[164]. Business Operations and Developments - The company has expanded its product line in the over-the-counter drug sector, enhancing the "Kuaike" brand into a multi-product series, significantly increasing brand recognition[28]. - The company has developed the "Jinxing" capsule, which contains 16.20% of ginsenoside Rh2, leading the market in its category and showing promising sales growth[28]. - The company has successfully developed multiple innovative Western medicine products and modern Chinese medicine, including the "Xuduan Zhuanggu" capsule, which is recognized as a national new drug[29]. - The company is advancing its research and development in steel-reinforced plastic composite pipe technology, filling a domestic gap and achieving international advanced levels[30]. - The company has initiated a new business in vacuum coating equipment through a subsidiary, targeting the solar thermal utilization industry[33]. - The vertical circulation parking garage project is being actively promoted, addressing the growing parking challenges in major cities[33]. - The company is focusing on R&D in areas such as cancer, antiviral treatments, and osteoporosis, with plans to expand into diabetes and Alzheimer's[41]. - The company plans to expand its traditional Chinese medicine product line, leveraging local partnerships and brand effects to enhance market presence[46]. Financial Management and Investments - The company has established a comprehensive quality assurance system, adhering to GMP and GSP standards, ensuring stable product quality[39]. - The company has a concentrated product structure, with the 快克 cold medicine series accounting for a significant portion of revenue and gross profit[70]. - The company has established stable long-term relationships with major suppliers, mitigating risks related to raw material shortages[69]. - The company has committed to not transferring shares for 36 months following the issuance of shares in a recent transaction[78]. - The company will ensure that its management and related parties maintain independence from the company to protect the interests of minority shareholders[79]. - The company guarantees complete independence of assets between itself and its controlling entities[79]. - The company has established a complete and independent organizational structure to support its operational autonomy[80]. - The company has committed to compensating any losses incurred due to violations of independence commitments by controlling parties[81]. Legal and Compliance Matters - The company has not engaged in any significant related party transactions during the reporting period[102]. - The company has not reported any new product launches or technological advancements during this period[168]. - The company has committed to compensating investors for losses caused by any false statements or omissions in the IPO prospectus[93]. - The company will freeze its own funds equivalent to the amount raised from the IPO to ensure compensation for investors if necessary[93]. - The company has made commitments to avoid competition with other businesses controlled by its executives[92]. - The company has confirmed timely fulfillment of commitments made to minority shareholders[93]. - The company will announce any share repurchase or compensation plans within two trading days if the IPO prospectus is found to contain false statements or omissions[89]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 12,949[124]. - The largest shareholder, Kuai Yixi, holds 16.63% of the shares, totaling 66,793,680 shares[124]. - The second-largest shareholder, Gao Yaping, holds 13.25% of the shares, totaling 53,245,040 shares[124]. - The total number of shares before the change is 401,743,800, with no new shares issued or changes in the number of shares[122]. - The proportion of limited sale shares remains at 42.41%, totaling 170,384,000 shares[122]. - The proportion of unrestricted shares is 57.59%, totaling 231,359,700 shares[122]. Market Risks and Challenges - The company faces market risks due to increasing competition in the cold medicine and health food sectors, which may affect market share[69]. - The company faces risks related to the approval of new drug registrations, which could impact the recovery of R&D investments if products do not meet market demand[71]. - The company is monitoring the impact of the COVID-19 pandemic on its operations, which may have temporary effects depending on the progression of the pandemic and local policies[72]. - The company's main products, including "Kuaike," are classified as low-priced drugs, which may face potential price reduction risks under future government policies[72]. Audit and Reporting - The semi-annual report has not been audited, indicating a lack of external validation for the financial data presented[94]. - The company has not conducted an audit for the semi-annual financial report[94]. - There are no major litigation or arbitration matters during the reporting period[96]. - The company has not experienced any bankruptcy restructuring during the reporting period[95]. - There are no non-standard audit reports from the previous year[95].

Financial Performance - The company reported a total revenue of 401,743,872.00, with a cash dividend of 0.7 yuan per 10 shares to all shareholders[10]. - The company's operating revenue for 2019 was CNY 1,005,606,188.19, representing a 3.59% increase compared to CNY 970,716,005.65 in 2018[22]. - The net profit attributable to shareholders for 2019 was CNY 120,334,377.62, a decrease of 19.32% from CNY 149,153,327.68 in 2018[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 110,154,009.03, down 22.04% from CNY 141,295,164.64 in 2018[22]. - The net cash flow from operating activities was CNY 186,467,495.08, a decline of 6.34% compared to CNY 199,082,344.96 in 2018[22]. - The total assets at the end of 2019 amounted to CNY 3,230,264,178.78, reflecting a 1.24% increase from CNY 3,190,770,641.08 at the end of 2018[22]. - The net assets attributable to shareholders at the end of 2019 were CNY 2,732,504,696.54, up 3.34% from CNY 2,644,309,828.68 at the end of 2018[22]. - The basic earnings per share for 2019 was CNY 0.30, down 18.92% from CNY 0.37 in 2018[22]. - The diluted earnings per share for 2019 was also CNY 0.30, reflecting the same percentage decrease of 18.92% from CNY 0.37 in 2018[22]. - The weighted average return on equity for 2019 was 4.45%, a decrease of 1.32% from 5.77% in 2018[22]. Product Development and R&D - The company is focusing on developing targeted biological agents and anti-tumor drugs as future key development areas[8]. - The company has multiple innovative Western medicine products, including "Kuaike Tai" and "Xiluotazuo" tablets, showcasing its strong R&D capabilities[32]. - The company is focusing on R&D in areas such as anti-cancer and anti-viral drugs, with several innovative products recognized by national programs[46]. - The company is conducting clinical trials for Yijinshi capsules and has made progress in the development of targeted drug carriers and new diabetes treatments[52]. - Research and development expenses amounted to ¥28.5 million, representing a 2.21% increase compared to the previous year[66]. - The company is investing in R&D, allocating 100 million yuan towards the development of new technologies and products in the upcoming year[109]. - Investment in research and development increased by 30%, focusing on innovative drug formulations and advanced manufacturing technologies[113]. Market Position and Competition - The main products, including the "Kuaike" cold medicine series, significantly contribute to the company's revenue, indicating a high dependency on a few key products[7]. - The company faces risks from increasing competition in the cold medicine and health food markets, which may threaten its market share[6]. - The company has a strong competitive advantage in the healthcare sector, with its products achieving high brand recognition and sales growth year over year[31]. - The company has a strong brand presence in the OTC drug market, with KuaiKe ranking 6th in the adult cold medicine market with a market share of 6.59%[41]. - The company is actively enhancing its product portfolio, particularly for the KuaiKe and XiaoKuaiKe brands, which generated ¥544,331,426.60, accounting for 54.13% of total revenue[57]. Financial Risks and Challenges - The company acknowledges potential impacts from the COVID-19 pandemic on its production and operations, depending on the progression of the pandemic[9]. - The company is exposed to risks related to the approval process for new products, which could affect its future profitability if new drugs do not meet market demand[8]. - The company has a risk of price fluctuations for its low-priced drugs due to government pricing policies, which could impact its revenue[9]. - The health food segment faced a significant decline, with revenue dropping by 31.53% to ¥36,093,657.84 from ¥52,715,891.62 in 2018[58]. Strategic Initiatives and Investments - The company has established long-term stable partnerships with major suppliers, ensuring a steady supply of raw materials[6]. - The company has developed a new generation of composite pipe production equipment, which significantly reduces material consumption and costs compared to traditional materials[34]. - The company is actively promoting the vertical circulation parking garage project, which addresses the growing parking difficulties in major cities due to increasing car ownership[37]. - The company has established a subsidiary for the research and production of vacuum coating equipment, targeting the solar thermal utilization industry with promising growth prospects[36]. - The company increased its investment in Hangzhou Lingye Pharmaceutical Technology Co., leading to significant changes in equity assets[38]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 200 million yuan earmarked for potential mergers and acquisitions[109]. Shareholder and Governance Matters - The cash dividend for the year was set at 0.70 CNY per 10 shares, totaling 28,122,071.00 CNY, which represents 26.97% of the total profit distribution[102]. - The company has fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[106]. - The company guarantees that its financial department operates independently from other entities under the control of the commitment party[108]. - The company has established a governance structure to maintain operational independence and protect the interests of minority shareholders[108]. - The company will not provide guarantees for the debts of the commitment party or its affiliates[108]. Future Outlook - Future outlook includes a projected revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies[109]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[177]. - The company aims to enhance the efficiency of its fundraising projects by relocating the R&D office building construction to Chengdu, which is expected to attract more talented R&D personnel[90]. - The company is set to launch three new products in the upcoming quarter, which are anticipated to contribute an additional 200 million CNY in revenue[177]. Legal and Compliance Issues - The company is involved in ongoing litigation related to trademark infringement and unfair competition, with an estimated amount of 3 million RMB at stake[128]. - The company has ongoing litigation with Zhejiang Yake Pharmaceutical Co., Ltd. regarding a design contract dispute, with an amount of 814,100 RMB involved[128]. - The company has not reported any instances of misleading statements or significant omissions in its public offering documents, safeguarding investor interests[119]. Employee and Management Matters - The total remuneration paid to directors, supervisors, and senior management for the reporting period amounted to CNY 6.0423 million[179]. - The company employed a total of 1,682 staff, including 422 production personnel, 757 sales personnel, and 229 technical personnel[181]. - The company has established a comprehensive employee compensation system, adjusting salaries annually based on market conditions and internal promotion needs[183]. - Training programs are conducted combining internal and external training to enhance employee skills and management capabilities[184].

Financial Performance - Total revenue for Q1 2020 was ¥208,017,683.01, a decrease of 25.28% compared to ¥278,409,800.93 in the same period last year[8]. - Net profit attributable to shareholders was ¥19,698,254.47, down 61.70% from ¥51,428,761.57 year-on-year[8]. - Basic earnings per share decreased by 61.54% to ¥0.05 from ¥0.13 in the previous year[8]. - The net cash flow from operating activities was -¥59,146,139.57, showing a slight improvement of 5.41% compared to -¥62,525,934.41 in the same period last year[8]. - Total assets at the end of the reporting period were ¥3,177,982,033.40, a decrease of 1.62% from ¥3,230,264,178.78 at the end of the previous year[8]. - The weighted average return on net assets was 0.72%, down from 1.93% in the previous year, a decline of 1.21%[8]. - The company reported non-recurring gains and losses totaling ¥1,313,146.43 for the period[9]. - The significant decline in revenue and profit was attributed to the impact of the COVID-19 pandemic[16]. - The company reported a significant increase in revenue for Q1 2020, with a year-over-year growth of 16%[31]. - The company reported a net profit margin of 12%, which is an improvement from 10% in the previous quarter[31]. - The total profit for the current period is ¥24,977,951.27, down from ¥63,853,001.12, indicating a decline of approximately 60.9%[62]. - Net profit for the current period is ¥19,404,610.74, down from ¥52,017,519.72, reflecting a decrease of around 62.7%[63]. Shareholder Information - The total number of shareholders at the end of the reporting period was 401,743,872[12]. - The top shareholder, 蒯一希, held 16.63% of the shares, amounting to 66,793,680 shares[12]. Business Strategy and Development - The company plans to continue developing its existing business in specialized equipment technology and maintain its market position despite economic slowdowns[27]. - The completion of the acquisition of Asia Pharmaceutical is expected to significantly reduce the impact of economic cycles on the company's performance[27]. - The company aims to accelerate the development of new products to maintain its technological leadership in the industry[27]. - The company is focused on developing new products, including targeted biological agents and anti-tumor drugs, but faces risks related to product approval and market acceptance[22]. - The company is expanding its product line under the "Kuaike" brand for adult respiratory medications and "Xiaokuaike" for children's medications to enhance brand influence and support revenue growth[28]. - The company is actively developing various sales channels for "Jinxing Capsules" to increase brand awareness and sales scale in the high-end health products market[28]. - A dedicated department has been established to conduct mergers and acquisitions steadily, aiming to optimize business structure and enhance profitability and risk resistance[28]. - The company is considering strategic acquisitions to enhance its market position, with a target of identifying at least two potential candidates by Q4 2020[31]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development in 2020[31]. Operational Independence and Governance - The company reported a significant commitment to maintaining operational independence across personnel, assets, finance, and business activities[32]. - The commitment includes ensuring that no senior management from the company is employed by related parties, maintaining a clear separation of financial management systems[32]. - The company guarantees that its assets and operations remain independent from those of related parties, preventing any illegal appropriation of funds[32]. - Financial independence is emphasized, with the company maintaining separate accounting and banking systems from related parties[32]. - The company aims to enhance its market independence and operational capabilities by minimizing related party transactions[32]. - The commitment to independence extends to governance structures, ensuring that decision-making processes are not interfered with by related parties[32]. - The company has outlined measures to protect the interests of minority shareholders through strict adherence to independence principles[32]. - The company will not provide guarantees for the debts of related parties, reinforcing its financial autonomy[32]. - The commitment to independence is legally binding, with provisions for compensation in case of violations[32]. - The company will not engage in any transactions that compromise its operational independence, ensuring a focus on sustainable growth[32]. Compliance and Regulatory Commitments - The company has made a commitment to bear any penalties or fees related to existing asset defects, ensuring no financial burden falls on its subsidiaries[37]. - The company has pledged to fully cover any required contributions to housing provident funds as mandated by government authorities, ensuring compliance with regulations[37]. - The company has acknowledged potential liabilities related to land use and has committed to bear any penalties or claims arising from such issues[37]. - The company has confirmed that it has complied with housing provident fund regulations since 2009, addressing previous non-compliance issues[37]. - The company has established strict protocols for related party transactions, ensuring transparency and adherence to legal procedures[36]. - There is a clear commitment to avoid any conflicts of interest that may arise from related party dealings, with penalties for non-compliance outlined[36]. - The company is actively monitoring and managing potential competitive activities from its controlling shareholders to safeguard its business interests[36]. - The company has outlined measures to ensure that any related party transactions are conducted at fair market value to prevent any economic losses[36]. - The commitment letter from the controlling shareholders is legally binding, ensuring accountability and adherence to the outlined commitments[36]. - The company is prepared to take legal action against any breaches of the commitments made by its controlling shareholders[36]. Initial Public Offering (IPO) Plans - Sichuan Jinshi Asia Pharmaceutical Co., Ltd. plans to apply for the initial public offering of RMB ordinary shares (A shares) and list on the Growth Enterprise Market[38]. - The company has committed to ensuring the IPO prospectus is true, accurate, and complete, with a promise to compensate investors for any losses due to false statements or omissions[39]. - The company will adhere to the shareholding restrictions and voluntary lock-up commitments for shares held prior to the IPO[39]. - The company guarantees that the full set of documents for the IPO does not contain false records, misleading statements, or major omissions[40]. - The company will ensure compliance with laws and regulations during the share reduction process[40]. - The company will publicly explain any failure to fulfill commitments and apologize to investors[40]. - The company will compensate investors for any losses caused by violations of commitments[40]. - The company will not apply for public issuance of securities within 12 months if it violates the commitments[40]. - The company has made commitments to avoid competition and regulate related party transactions[40]. - The company will return any profits obtained from unfulfilled commitments to the designated account within five working days[42].

四川金石亚洲医药股份有限公司 2019 年第三季度报告全文 四川金石亚洲医药股份有限公司 2019 年第三季度报告 2019-045 2019 年 10 月 1 四川金石亚洲医药股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人蒯一希、主管会计工作负责人纪宏杰及会计机构负责人(会计主 管人员)何崇惠声明：保证季度报告中财务报表的真实、准确、完整。 2 四川金石亚洲医药股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 3,085,402,226.12 | | 3,190,770,641.08 | -3.30% | ...

Intellectual Property and Technology - The company has 38 national patents in specialized equipment technology, including 12 invention patents and 26 utility model patents[8]. - The company emphasizes the importance of protecting its proprietary technology to maintain its competitive advantage[8]. - The company has developed advanced technology for steel-reinforced plastic composite pipes, filling a domestic gap and achieving international advanced levels[34]. - The company is involved in setting industry standards for new types of pipeline products, enhancing its technological leadership[34]. - The company has developed two new types of steel-reinforced plastic composite pipes, which are expected to significantly reduce material consumption and costs compared to traditional plastic pipes[35]. - The winding steel wire reinforced pipe production line is designed for underground pressure pipes, with a diameter specification below Φ1000mm, offering superior resistance to rapid stress cracking and creep compared to plastic solid wall pipes[35]. - The steel belt reinforced plastic pipe production line has a diameter range from 250mm to 3000mm, primarily used for municipal drainage and sewage, providing a cost-effective alternative to traditional materials like concrete and cast iron pipes[36]. - The company is engaged in the research and development of specialized equipment and pharmaceutical health products[33]. Business Expansion and Acquisitions - The acquisition of Asia Pharmaceutical has been completed, granting the company 100% ownership, which adds over-the-counter drugs and health food to its business portfolio[9]. - The integration of the acquired Asian Pharmaceutical has positively impacted the company's pharmaceutical manufacturing business, maintaining a strong growth momentum[55]. - The company is actively exploring overseas markets and has upgraded the packaging for its "今幸" product line to enhance market appeal[54]. - The company aims to expand its product range in vacuum coating equipment and enhance its market position through the development of higher absorption rate films and coating technologies[37]. - The vertical circulation parking garage project, based on technology from DONGYANG PC, INC, is expected to become a significant profit source due to the increasing demand for parking solutions in urban areas[38]. Financial Performance - Total revenue for the reporting period was CNY 419,719,990.63, a decrease of 1.95% compared to the same period last year[25]. - Net profit attributable to shareholders was CNY 51,107,158.16, an increase of 2.55% year-on-year[25]. - Net profit after deducting non-recurring gains and losses was CNY 49,518,248.60, reflecting a growth of 7.08% compared to the previous year[25]. - The net cash flow from operating activities decreased by 34.08% to CNY 72,446,576.27[25]. - Basic earnings per share increased by 8.33% to CNY 0.13 per share[25]. - Total assets at the end of the reporting period were CNY 3,036,313,066.73, down 4.84% from the end of the previous year[25]. - Net assets attributable to shareholders increased by 0.72% to CNY 2,663,277,477.08[25]. - The company reported a significant increase in revenue for the first half of 2019, with a year-on-year growth of 20%[95]. - The company reported a total revenue of 300 million in the first half of 2019, representing a growth of 20% compared to the same period last year[107]. Risks and Challenges - The company faces risks related to economic cycle fluctuations, which could impact sales due to government infrastructure investment cuts[5]. - The company is at risk of goodwill impairment if Asia Pharmaceutical's future performance does not meet expectations, which could significantly affect current profits[11]. - The company acknowledges the risk of business transformation challenges as it expands into new markets and product lines[9]. - The company plans to invest in new projects, including technology for polyethylene spiral corrugated pipes, which may affect short-term profitability due to increased depreciation[81]. - The implementation of the "4+7" policy in the pharmaceutical industry is expected to create both challenges and opportunities for the company, emphasizing the need for a clear strategic direction[53]. Corporate Governance and Compliance - The company ensures that its financial department operates independently from other entities controlled by the shareholders, maintaining financial independence[89]. - The company has established a commitment to not allow any illegal occupation of its funds or assets by related parties[89]. - The company will publicly disclose any failure to fulfill commitments and apologize to shareholders if such violations occur[89]. - The company has a strategy to maintain the independence of its operations and protect the interests of minority shareholders[89]. - The company guarantees that its tax payments are independent of other entities controlled by the promisor[90]. - The company emphasizes the independence of its operational assets, personnel, and qualifications from those of the promisor[90]. - The company commits to not allowing controlling parties to interfere with its business activities beyond exercising shareholder rights[91]. - The company has established measures to protect its financial independence from related parties[91]. Research and Development - The company has developed a standardized new product R&D process, ensuring efficiency and value while minimizing opportunity costs associated with unmarketable products[45]. - The company is focusing on optimizing existing products and developing new ones in response to market demands, leveraging its advanced R&D capabilities[52]. - The company is investing in R&D, with a budget increase of 30% for new technology development in 2020[95]. - The company is focusing on enhancing its technological capabilities to support future growth initiatives[171]. Market Outlook and Future Plans - The company anticipates that ongoing urbanization and infrastructure investment will provide favorable conditions for its development in the coming years[5]. - The company provided a positive outlook for the second half of 2019, projecting a revenue increase of 15% to 20% compared to the first half[95]. - New product launches are expected to contribute an additional 10% to revenue growth in the upcoming quarters[95]. - Market expansion plans include entering two new international markets by the end of 2019, aiming for a 5% market share in each[95]. - The company plans to continue focusing on market expansion and new product development to drive future growth[154]. Legal Matters - The company is involved in a patent infringement dispute with a claim amounting to 500,000 yuan[105]. - The company is currently involved in multiple legal disputes, including patent infringement cases, with ongoing appeals in various courts[107]. - There are no major litigation or arbitration matters during the reporting period[105]. Shareholder Information - The company has committed to a 36-month lock-up period for shares held prior to the IPO, with restrictions on transfer or management delegation[96]. - The controlling shareholders have pledged to avoid related party transactions except for necessary remuneration and dividends[96]. - The company guarantees that all documents related to the initial public offering do not contain false records, misleading statements, or significant omissions[98]. - The company will disclose any unfulfilled commitments in the shareholders' meeting and apologize to other shareholders and public investors[98].

四川金石东方新材料设备股份有限公司 2019 年第一季度报告全文 四川金石东方新材料设备股份有限公司 2019 年第一季度报告 2019-020 2019 年 04 月 1 四川金石东方新材料设备股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人蒯一希、主管会计工作负责人纪宏杰及会计机构负责人(会计主 管人员)何崇惠声明：保证季度报告中财务报表的真实、准确、完整。 2 四川金石东方新材料设备股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 278,409,800.93 | 260,375,676.00 | 6.93% | | 归属于上市公司股东的净利润 ...

Patents and Technology - The company has a total of 38 national patents in specialized equipment technology, including 12 invention patents and 26 utility model patents[8]. - The company emphasizes the importance of patent protection to maintain its competitive advantage in the market[8]. - The company focuses on the research and development of specialized equipment and pharmaceutical health products, with a significant emphasis on steel-reinforced plastic composite pipe technology[34]. - The company has developed two main types of production lines: the winding steel wire reinforced pipe production line and the steel belt reinforced plastic pipe production line, which have strong market competitiveness and high economic benefits[35]. - The winding steel wire reinforced pipe can replace traditional plastic and steel pipes, significantly reducing material consumption and costs due to its thinner wall thickness under the same internal pressure conditions[35]. - The steel belt reinforced plastic pipe, with diameters ranging from 250mm to 3000mm, is primarily used for municipal drainage and sewage, offering superior performance compared to traditional materials[36]. Acquisitions and Business Expansion - The company completed the acquisition of Asia Pharmaceutical, holding 100% equity, which significantly increases its business scope to include over-the-counter drugs and health food[9]. - The company’s original business focused on steel-reinforced plastic composite pipe technology, which has now expanded significantly due to the acquisition[9]. - The company aims to enhance brand building and operational efficiency in the pharmaceutical sector, leveraging the advantages of Asia Pharmaceutical's brand and sales channels[96]. Financial Performance - The company's operating revenue for 2018 was approximately ¥970.72 million, representing a 37.88% increase compared to ¥704.01 million in 2017[24]. - The net profit attributable to shareholders for 2018 was approximately ¥149.15 million, an increase of 28.46% from ¥116.11 million in 2017[24]. - The net cash flow from operating activities for 2018 was approximately ¥199.08 million, which is a 15.20% increase from ¥172.82 million in 2017[24]. - The total assets at the end of 2018 were approximately ¥3.19 billion, reflecting a 1.99% increase from ¥3.13 billion at the end of 2017[24]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥2.64 billion, a 4.95% increase from ¥2.52 billion at the end of 2017[24]. - The basic earnings per share for 2018 remained at ¥0.37, unchanged from 2017[24]. - The company reported a total of ¥7.86 million in non-recurring gains for 2018, compared to ¥4.31 million in 2017[30]. - The company experienced a significant increase in quarterly revenue, with Q4 2018 revenue reaching approximately ¥360.06 million[26]. Investment Projects - The company plans to invest in projects including the industrialization of steel belt reinforced polyethylene spiral corrugated pipe technology, vertical circulation parking garage, and new composite pipe R&D base[6]. - The vertical circulation parking garage project is a key investment initiative, addressing the growing parking demand in urban areas, with a market growth rate of 5.2% in new mechanical parking spaces installed in 2015[39]. - The company has developed proprietary technology for the vertical circulation parking garage, enhancing its competitiveness in the market[40]. - The company has ongoing projects, including the steel belt reinforced polyethylene spiral corrugated pipe technology and manufacturing equipment industrialization project, with an investment of ¥2.48 million in the reporting period[77]. Risks and Challenges - The company faces risks related to economic cycle fluctuations, which could impact sales due to reduced government infrastructure investment[5]. - The implementation of investment projects may lead to increased depreciation and amortization expenses, affecting short-term profitability[7]. - The company acknowledges the uncertainty in project implementation and market development, which may affect performance[7]. - The company is at risk of goodwill impairment if the future operating performance of Asia Pharmaceutical does not meet expectations[11]. - The company faced challenges in the mechanical manufacturing sector due to economic slowdown but leveraged its R&D capabilities to upgrade products[48]. Cash Dividends and Profit Distribution - The profit distribution plan includes a cash dividend of 0.80 RMB per 10 shares (tax included) based on a base of 401,743,872.00 RMB[11]. - The total cash dividend for the reporting period was CNY 32,139,510, representing 22.03% of the total distributable profit[102]. - The cash dividend for 2018 represents 21.55% of the consolidated net profit attributable to shareholders[105]. - The company has consistently increased its cash dividends over the past three years, with a notable increase from RMB 6,800,000.00 in 2016 to RMB 32,139,510.00 in 2018[105]. Research and Development - The company has initiated a clinical study for the Yijinshi capsule, with a new II phase clinical exploration research plan completed[67]. - R&D expenses rose by 32.44% from 21,085,316.38 yuan in 2017 to 27,924,816.90 yuan in 2018, representing 2.88% of total revenue[68]. - The company is investing 50 million CNY in R&D for new technologies to improve product efficiency and sustainability[111]. - The company has established a partnership with a leading university for collaborative research, which is expected to yield significant advancements in material science[182]. Corporate Governance and Compliance - The company has established a complete and independent organizational structure to enhance corporate governance[109]. - The company emphasizes maintaining independence from related parties to protect the interests of minority shareholders[108]. - The company has committed to fair and timely information disclosure, designating a board secretary to manage investor relations[195]. - The company has a governance structure that complies with the requirements of the Company Law and the Shenzhen Stock Exchange regulations[194]. Shareholder Commitments and IPO Plans - The company plans to apply for an initial public offering of RMB ordinary shares (A shares) and list on the Growth Enterprise Market[115]. - The controlling shareholder and actual controller, Kuai Yixi, has committed to not transferring or entrusting the management of shares for 36 months post-IPO[115]. - The company commits to timely reporting of shareholding changes and will face penalties for non-compliance with lock-up commitments[117]. - The company will publicly disclose any failure to fulfill commitments regarding share transfers and will be liable for any resulting losses[116]. Employee Management and Compensation - The total number of employees in the company is 1,617, with 1,495 in major subsidiaries and 122 in the parent company[189]. - The company has established a comprehensive employee compensation system, adjusting salaries annually based on market conditions and internal promotion needs[190]. - Training programs include a combination of internal and external training to enhance employee skills and management capabilities[191]. - The company emphasizes employee satisfaction through various incentive measures to enhance work efficiency and profitability[190].

Financial Performance - Operating revenue increased by 2.95% to CNY 182,578,739.86 for the current period, and by 90.57% to CNY 610,657,498.47 year-to-date[6] - Net profit attributable to shareholders increased by 113.63% to CNY 66,185,315.66 year-to-date, despite a 4.46% decrease in the current period[6] - Basic earnings per share decreased by 12.50% to CNY 0.07 for the current period, while year-to-date it increased by 57.89% to CNY 0.30[6] - The weighted average return on net assets decreased by 47.54% to 0.64% for the current period, and by 64.67% to 2.60% year-to-date[6] - Total operating revenue for the third quarter was CNY 182,578,739.86, an increase of 2.0% compared to CNY 177,338,979.71 in the same period last year[32] - Net profit for the period was CNY 16,490,013.31, a decrease of 6.5% from CNY 17,628,085.56 year-on-year[33] - Earnings per share (EPS) for the quarter was CNY 0.07, down from CNY 0.08 in the previous year[33] - The consolidated net profit for the year-to-date period is 66,921,459.52, an increase of 104.5% compared to 32,695,812.53 in the previous period[40] - Basic earnings per share for the current period is 0.30, compared to 0.19 in the previous period, reflecting a 57.9% increase[40] - The total comprehensive income for the current period is 66,921,459.52, compared to 32,695,812.53 in the previous period, marking a 104.5% increase[40] Assets and Liabilities - Total assets decreased by 4.70% to CNY 2,981,731,598.41 compared to the end of the previous year[6] - Total assets decreased from ¥3,128,647,569.00 to ¥2,981,731,598.41, a decline of about 4.7%[25] - Total liabilities decreased from ¥574,952,252.03 to ¥385,665,836.32, a reduction of approximately 33%[25] - The company's total assets decreased to CNY 2,461,164,055.41 from CNY 2,502,122,634.29 at the beginning of the period[30] - Current assets totaled CNY 234,963,989.88, down from CNY 276,746,444.59, primarily due to a reduction in cash and inventory[28] Cash Flow - The company reported a net cash flow from operating activities of CNY 166,694,391.08, an increase of 107.58% year-to-date[6] - Cash inflow from operating activities totaled CNY 818,187,520.93, up from CNY 369,189,682.69, representing a growth of 121.1%[45] - Cash outflow from investing activities was CNY 216,619,258.88, significantly reduced from CNY 1,060,382,765.75, indicating a decrease of 79.6%[46] - The net cash flow from investing activities improved to CNY 21,080,298.14 from a negative CNY 739,043,513.44, marking a turnaround[46] - The net cash flow from financing activities was negative at CNY -74,649,213.57, compared to a positive CNY 760,567,825.58 in the previous period[46] - The ending cash and cash equivalents balance increased to CNY 305,422,955.02 from CNY 168,508,782.42, a rise of 81.2%[46] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,754[10] - The top ten shareholders held a combined 64.06% of the shares, with the largest shareholder holding 16.63%[10] - The company declared a cash dividend of ¥1.10 per 10 shares, totaling ¥24,551,014.40, based on the total share capital as of December 31, 2017[17] - The company approved a capital reserve conversion plan, increasing share capital by 178,552,832 shares, resulting in a new total of 401,743,872 shares[18] Non-Recurring Gains and Losses - Non-recurring gains and losses included government subsidies totaling CNY 4,354,787.34[7] - The company did not identify any non-recurring gains and losses as regular income during the reporting period[8] Research and Development - Research and development expenses were CNY 4,690,309.25, a decrease from CNY 5,486,494.11 in the previous year[32] - Research and development expenses for the current period are 1,660,901.82, down 15.9% from 1,974,499.71 in the previous period[36] Other Financial Metrics - The company recorded investment income of CNY 494,767.01, an increase from CNY 279,720.24 year-on-year[33] - The company reported investment income of 371,737.78, an increase from 210,064.00 in the previous period[36] - Financial expenses decreased significantly to 42,437.67 from 7,111,791.58 in the previous period, indicating a reduction of 99.4%[36] - The company reported a significant reduction in short-term borrowings, decreasing to CNY 10,000,000.00 from CNY 45,000,000.00[29]

Financial Performance - The company reported a net profit commitment for Asia Pharmaceutical of CNY 126.5981 million, CNY 280.4708 million, and CNY 444.3464 million for the respective years during the performance commitment period[7]. - The completion rate of Asia Pharmaceutical's profit commitment for 2016-2017 was 104.36%, indicating strong profitability during the reporting period[7]. - Total revenue for the first half of 2018 reached ¥428,078,758.61, representing a 199.16% increase compared to ¥143,094,179.98 in the same period last year[23]. - Net profit attributable to shareholders was ¥49,836,936.02, a significant increase of 259.31% from ¥13,869,988.50 year-on-year[23]. - Net profit after deducting non-recurring gains and losses was ¥46,242,613.37, up 293.98% from ¥11,737,240.29 in the previous year[23]. - Operating cash flow net amount was ¥109,894,641.99, reflecting a 67.78% increase compared to ¥65,501,174.57 in the same period last year[23]. - Basic earnings per share increased to ¥0.22, a 120.00% rise from ¥0.10 in the previous year[23]. - The company achieved a revenue of CNY 428,078,758.61, representing a year-on-year growth of 199.16%[51]. - The net profit attributable to shareholders was CNY 49,836,936.02, with a year-on-year increase of 259.31%[51]. - The pharmaceutical manufacturing sector generated revenue of CNY 325,284,212.69, showing a significant growth of 507.33% and a gross margin of 72.23%[51]. - The specialized equipment manufacturing sector reported revenue of CNY 84,712,091.63, which is a slight decline of 2.18% with a gross margin of 32.94%[51]. - The real estate leasing and management sector achieved revenue of CNY 18,082,454.29, marking a growth of 516.75% and a gross margin of 25.92%[51]. Investment and Projects - The company plans to invest in projects such as the industrialization of steel belt reinforced polyethylene spiral corrugated pipe technology, which will significantly enhance production capacity and R&D capabilities[4]. - The company has committed to invest a total of CNY 14,740.57 million in various projects, with a cumulative investment of CNY 12,774.51 million by the end of the reporting period, achieving a progress rate of 86.67%[69]. - The "Steel Belt Enhanced Polyethylene Spiral Corrugated Pipe Technology and Manufacturing Equipment Industrialization Project" has a total investment of CNY 7,000 million, with a cumulative investment of CNY 6,554.62 million, representing 94.00% completion as of September 30, 2018[69]. - The "New Composite Pipeline R&D and Experimental Base Construction Project" has a total investment of CNY 4,740.57 million, with a cumulative investment of CNY 3,693.98 million, achieving 78.00% completion by December 31, 2018[69]. - The "Vertical Circulation Stereoscopic Parking Garage Project" has a total investment of CNY 3,000 million, with a cumulative investment of CNY 2,525.91 million, representing 84.00% completion by December 31, 2018[69]. Risks and Challenges - The company faces risks related to economic cycle fluctuations, which could impact sales due to the correlation with national economic development and fixed asset investment growth[4]. - The company has a risk of goodwill impairment due to the acquisition of Asia Pharmaceutical, which may affect current profits if future performance does not meet expectations[9]. - The company has a risk of integration challenges post-acquisition, as it needs to align corporate culture, management, and operational strategies with Asia Pharmaceutical[5]. - The company has raised concerns about potential risks from technology leaks or patent infringements that could negatively impact operations[5]. - The company has outlined risks associated with fundraising projects, which may face uncertainties in implementation and market development, potentially affecting performance[4]. Product Development and Market Expansion - The company is focused on expanding its product lines, including the development of new composite pipeline technologies[16]. - Future outlook includes continued investment in R&D and potential market expansion strategies[16]. - The company has developed multiple innovative Western medicine products, including "Kuaiketa" and "Xilota", and is preparing to launch the traditional Chinese medicine "Xuduan Zhuanggu Capsule" into the market[40]. - The company is actively expanding into high-barrier markets such as large vacuum coating technology and equipment manufacturing[43]. - The company is focusing on expanding its product offerings in the pharmaceutical sector, particularly in response to common and serious infections[52]. Compliance and Governance - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for pharmaceutical businesses[52]. - The company emphasizes the importance of maintaining independence from its controlling shareholders to protect the interests of minority shareholders[100]. - The company guarantees that its financial department and accounting system will remain completely independent from other entities controlled by the shareholders[100]. - The company will ensure that its management structure is independent and complete, promoting independent operations[100]. - The company will take legal measures to fulfill its commitments and will be liable for any losses caused by violations of these commitments[100]. Shareholder Commitments - The company proposed a capital reserve transfer plan, with a distribution of 8 shares for every 10 shares held, resulting in a total increase of 178,552,832 shares, bringing the total share capital to 401,743,872 shares[97]. - The company did not declare any cash dividends or bonus shares for the reporting period, maintaining a focus on capital reserve transfers[96]. - The commitment from the controlling shareholder includes a lock-up period of 36 months for shares subscribed through the transaction[98]. - The company has committed to lock up shares acquired through the Tian Tang Silicon Valley - Jinshi private placement for 36 months from the completion of the issuance[99]. - The company will ensure compliance with the relevant regulations regarding share transfers and lock-up periods post-IPO[109]. Legal and Regulatory Matters - There is a pending patent infringement lawsuit against Sichuan Lancheng Pipe Industry Co., Ltd. and Kunshan Tongsu Machinery Manufacturing Co., Ltd. with a claim amount of 1.5 million RMB[117]. - The company has not faced any penalties or rectification issues during the reporting period[120]. - The company confirmed that the prospectus for the initial public offering (IPO) is accurate and complete, ensuring investor protection[112]. - The company will bear legal responsibility for any losses incurred by investors due to non-compliance with commitments[112]. Future Outlook - The company provided a positive outlook for the second half of 2018, projecting a revenue growth of 10% to 15% based on current market trends[104]. - The company aims to enhance its R&D capabilities, increasing the R&D budget by 30% to support new technology initiatives[104]. - The company plans to apply for an initial public offering of RMB ordinary shares (A shares) and list on the Growth Enterprise Market[106]. - The company plans to implement a stock repurchase program if the stock price falls below the net asset value per share for 20 consecutive trading days within three years of listing[110].

Financial Performance - Total revenue for Q1 2018 reached ¥260,375,676, representing a 745.72% increase compared to ¥30,787,342 in the same period last year[7] - Net profit attributable to shareholders was ¥48,049,214, a significant turnaround from a loss of ¥5,583,610 in the previous year, marking a 960.54% increase[7] - The net profit after deducting non-recurring gains and losses was ¥45,286,891, compared to a loss of ¥6,472,892, reflecting a 799.64% improvement[7] - Basic and diluted earnings per share increased to ¥0.22 from a loss of ¥0.04, representing a 650.00% increase[7] - The weighted average return on net assets improved to 1.89%, up from -1.40% in the previous year[7] - The company reported a significant increase in sales expenses, which rose to CNY 80,466,829.15 from CNY 1,652,603.76, indicating aggressive market expansion efforts[74] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,078,778,711.97, a decrease of 1.59% from the previous year-end[7] - The net assets attributable to shareholders increased by 1.91% to ¥2,567,756,729.69 compared to the previous year-end[7] - The total assets of the company as of the end of Q1 2018 amounted to CNY 2,507,554,138.72, slightly up from CNY 2,502,122,634.29 at the end of the previous year[71] - Total liabilities decreased to CNY 477,032,149.77 from CNY 574,952,252.03, a reduction of approximately 16.98%[67] - Total liabilities increased to CNY 107,372,208.04 from CNY 101,386,797.70, reflecting a rise of 5.3%[71] Acquisitions and Investments - The acquisition of Asia Pharmaceutical has been completed, with the company holding 100% of its shares, aiming for operational synergies[12] - The company completed the acquisition of Asia Pharmaceutical, holding 100% equity, which significantly contributed to the financial data in Q1 2018 compared to the same period last year[25] - The financial indicators showed a substantial increase due to the inclusion of Asia Pharmaceutical's performance from January to March 2018[26] - The company plans to maintain a cash dividend policy, ensuring annual cash dividends are no less than 20% of the distributable profits[52] - The steel belt project is one of the fundraising projects aimed at expanding production capacity, with construction expected to be completed by June 2018[56] Shareholder Commitments and Governance - The company has committed to lock up shares for 36 months following the completion of the transaction, with specific conditions for release thereafter[32] - The commitments are binding and subject to oversight by regulatory authorities and the public[32] - The company has established a legal framework for the commitments, ensuring compliance with relevant laws and regulations[32] - The company has committed to not transferring shares held by its shareholders until all commitments are fully executed[40] - The company emphasizes the importance of compliance with regulations and maintaining shareholder trust through transparent practices[43] Market Expansion and Future Outlook - The company is exploring market expansion opportunities in Southeast Asia, targeting a 25% increase in market penetration by the end of 2018[39] - New product development is underway, with the launch of two innovative materials expected by Q3 2018, aimed at expanding market share[38] - The company provided a positive outlook for the upcoming quarters, projecting a revenue growth of 10-15% for the next fiscal year[39] - Management indicated plans for further market expansion and potential new product development in the upcoming quarters[74] Compliance and Regulatory Matters - The company has committed to repurchasing shares if the IPO prospectus contains false statements or omissions that materially affect investors[53] - The company emphasizes the importance of adhering to legal and regulatory requirements in all share transactions[50] - The company will disclose any related party transactions in a timely manner, adhering to legal procedures[42] - The company will report any changes in its shareholding promptly to the issuer[46] Cash Flow and Financial Health - The company reported a net cash flow from operating activities of -18,636,006.80 CNY, compared to -1,618,165.03 CNY in the previous period, indicating a significant increase in cash outflow[80] - Total cash inflow from operating activities was 268,171,283.06 CNY, a substantial rise from 34,140,402.49 CNY in the same period last year[80] - The company recorded a total cash outflow from operating activities of 286,807,289.86 CNY, compared to 35,758,567.52 CNY in the previous year[80] - The company has assured that it will not engage in any business activities that compete with its existing operations during the tenure of its shareholders and executives[40]